Who we work with

C4X Discovery operates a hybrid business model of a wholly owned pipeline of discovery programmes plus partnerships with global and international companies, from top 10 pharma through to biotech.

The Company is partnered with the Structural Genomic Consortium to assist with the identification and validation of new drug targets and has several active research collaborations with academic institutions.


Global top 10 Pharma
AstraZeneca in the UK has a focus on developing new medicines that make a meaningful difference to patients’ lives. AstraZeneca is a major contributor to UK science and innovation investment, economic prosperity and to patient health.


Largest Japanese Pharma
Takeda Cambridge has established world-class target identification and validation capabilities. Capitalising on these skills, Takeda Cambridge has developed a pipeline of novel compounds with promising potential to treat key areas of unmet medical need including Alzheimer’s disease, schizophrenia, diabetes, obesity and inflammatory diseases.


Largest European CRO
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. They operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.


Structural Genomic Consortium
The SGC is a world leader in public-private partnership that supports the discovery of new medicines through open access research. The SGC is backed by the Welcome Trust and major pharma including Bayer, Pfizer, Abbvie, Merck, J&J, Boehringer Ingelheim, Novartis and Takeda.

Research Collaborations